Renalytix plc (LON: RENX), a precision medicine company specializing in kidney disease diagnostics, has announced its intention to raise a minimum of £4.0 million through a placing, subscription, and retail offer.
The funds will support the continued commercialization and development of kidneyintelX.dkd, its FDA-approved prognostic test.
The company is issuing new ordinary shares at a price of 9.5 pence per share. This represents an 11.6% discount to the closing middle market price on September 19, 2025, but a 39% premium to the 90-day closing average share price. The placing will be conducted via an accelerated bookbuild, led by Oberon Capital.
Renalytix already has the necessary shareholder approvals to issue the new shares. The company secured these authorities at its annual general meeting in December 2024, demonstrating foresight in anticipating its capital needs.
Company directors intend to participate in the fundraise, committing approximately £270,000 in total. However, the directors' shares will be subject to a six-month lock-in period, preventing them from immediately selling their newly acquired shares.
The fundraise aims to fuel Renalytix's growth strategy, particularly the wider adoption of kidneyintelX.dkd. This test is currently the only FDA-approved and Medicare-reimbursed prognostic tool for early-stage risk assessment in chronic kidney disease.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Vantage High levels of account and deposit protection – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
